Researchers found that oxidized self-DNA drives acute kidney injury by activating the cGAS–STING pathway and NLRP3 inflammasome. A20 and its peptide P-II block NEK7–NLRP3 interaction, protecting against AKI and improving outcomes in mice. Learn more here:

Researchers identified TGFBR2 as a key driver of recurrent glioblastoma and treated mice models bearing orthotopic human rGBM xenografts with miR-590-3p-loaded nanoparticles, which suppressed tumor growth and extended survival. Learn more:

Researchers developed self-assembling, zone-specific human liver organoids that mimic real hepatic architecture, unlocking new paths for studying liver development, metabolism, and disease. Click here to learn more：

Researchers found that DNMT3A-mutant blood stem cells exploit mitochondrial metabolism for clonal expansion. Metformin blocks this pathway, restores epigenetic balance, and limits mutant growth—supporting its repurposing to target clonal hematopoiesis.

Researchers discovered that CTPS1 modifies histone H1 via deamidation and acetylation to relax chromatin during DNA repair. Elevated CTPS1 levels correlate with radiotherapy resistance, revealing a potential epigenetic vulnerability in cancer. Learn more:

Researchers found that bone metastases induce resistance to immune checkpoint blockade via osteoclast-derived osteopontin, which impairs CD8⁺ T cell priming. Targeting osteoclastogenesis or OPN restores ICB response—validated in clinical cohorts.

Novogene’s Falcon Series transforms high-throughput NGS with fully automated workflows and exceptional precision. It reflects our commitment to innovation—delivering higher accuracy, faster turnaround, and greater efficiency through advanced instruments and methods. #Genomics

Novogene empowers discovery through advanced genomics platforms capable of satisfying diverse research needs. We continuously upgrade our technologies and platforms to help researchers address challenges in their research. #Sequencing #Genomics #MolecularBiology #LifeSciences

Researchers analyzed 1,115 iNTS cases and identified S. Enteritidis as a major pathogen. They observed AMR to fluoroquinolones and 3rd-gen cephalosporins and found evidence suggesting possible human-to-human transmission. Just click here:

Novogene's commitment to borderless science is realized with its laboratories across the globe. Through our Global Localization Strategy, we serve research communities with globalized standards and localized expertise. #Genomics #LifeSciences #MolecularBiology #Sequencing

At Novogene, our vision to be the global leader in genomic services drives every step in our journey. Through cutting-edge sequencing solutions, we support researchers in various research fields in their efforts to explore the unknown and push scientific boundaries. #LifeSciences

Celebrate #WorldOceansDay with Novogene. 🌊🧬 Marine genomes reveal critical insights for safeguarding biodiversity, enhancing coral resilience, and advancing microbial solutions for ocean health. Witness how genomic science drives global conservation—one sequence at a time.

Celebrate #WorldEnvironmentDay with Novogene! Our genomics-driven insights are accelerating global conservation—from safeguarding biodiversity to enabling sustainable solutions. Together, let’s decode nature’s resilience for a healthier planet. Explore how science becomes action.

On #WorldBloodCancerDay, we stand with those fighting blood cancer. Advances in genomics and precision medicine are driving hope—bringing faster diagnoses, better treatments, and brighter futures. 🧬❤️ #BloodCancer #InnovationInHealthcare

Today on #InternationalDayForBiologicalDiversity, we celebrate the intricate code of life. Innovation in genomics and sequencing technology empowers us to explore, understand, and protect biodiversity for future generations. 🌍🔬 #Biodiversity #TechForGood

Researchers found ALKBH5 as a key regulator of metabolic disease. Upregulated in obesity, it disrupts glucose and lipid balance via GCGR and mTORC1. Hepatic Alkbh5 knockdown reversed T2DM and MAFLD in mice. Learn more:

Researchers developed immunocompetent in vivo and matched in vitro HCC models that reflect a range of features in human HCC. They revealed four shared human–mouse subtypes and identified cladribine as a new subtype-specific therapy. Just click here:

Researchers showed that fecal microbiota transplantation from HCC patients drove liver inflammation and cancer progression in mice. They identified Klebsiella pneumoniae as promoting cell proliferation and activating oncogenic signaling. Just click here:

Researchers uncovered a key metabolic switch driving MASH-to-HCC progression: loss of FBP1, a p53 target, reversed senescence in hepatocytes and fueled HCC progression via AKT/NRF2 activation. Click here to learn more：

Researchers revealed that loss of Kmt2c/d in urothelium disrupted differentiation, enhanced growth/inflammation responses, and increased susceptibility to malignant transformation. It upregulated EGFR signaling, creating vulnerability to EGFR inhibitors.